Targeting these factors can significantly impact the treatment of specific malignancies, as exemplified by the clinical success of agents targeting the androgen receptor (AR) in prostate cancer and estrogen receptor (ER) in breast cancer36. The gene discussed is ESR1; the disease is prostate carcinoma.